课题基金 / 基金详情

Optimization and Validation of MCT4-targeting Small Molecule Inhibitors for Treatment of Advanced Cancers

Optimization and Validation of MCT4-targeting Small Molecule Inhibitors for Treatment of Advanced Cancers
用于治疗晚期癌症的 MCT4 靶向小分子抑制剂的优化和验证
批准号:
451866
负责人:
Wang Yuzhuo
金额:
$83.6万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2021
资助国家:
加拿大
项目状态:
未结题
起止时间:
2021-09-01 至 2026-09-01

项目摘要

项目成果

Wang Yuzhuo的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Late-stage, therapy-resistant cancers remain difficult to treat and urgently requires better therapeutics. A common feature of advanced cancers is the altered processing of glucose (sugar) as an energy source. In contrast to normal cells, many cancer cell
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A master transcription factor driving cell lineage reprogramming in neuroendocrine prostate cancer development and progression
  • 批准号:
    472404
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
The role of PRDM16 in neuroendocrine prostate cancer development and aggressiveness
  • 批准号:
    420178
  • 项目类别:
    Operating Grants
  • 资助金额:
    $55.73万
  • 财政年份:
    2020
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
Function and therapeutic potential of SUV420H2 in neuroendocrine prostate cancer
  • 批准号:
    390460
  • 项目类别:
    Operating Grants
  • 资助金额:
    $69.66万
  • 财政年份:
    2018
  • 负责人:
    Wang Yuzhuo
  • 依托单位:
Identification of HP1a as a key regulator and a novel therapeutic target for neuroendocrine prostate cancer
  • 批准号:
    357156
  • 项目类别:
    Operating Grants
  • 资助金额:
    $55.73万
  • 财政年份:
    2016
  • 负责人:
    Wang Yuzhuo
  • 依托单位: